DelveInsight’s Anorexia Nervosa-Market Insights, Epidemiology, and Market Forecast–2032 report deliver an in-depth understanding of the Anorexia Nervosa, historical and forecasted epidemiology as well as the Anorexia Nervosa market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Anorexia Nervosa market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Anorexia Nervosa market size from 2019 to 2032. The Report also covers current Anorexia Nervosa treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Some of the key facts of the Anorexia Nervosa Market:
- The market size of Anorexia Nervosa is anticipated to increase during the study period, 2019–2032 in the 7MM
- Among the European countries, Germany had the highest diagnosed prevalent population of AN with 86,928 cases, followed by Italy with 71,967 cases in 2021. On the other hand, Spain had the lowest diagnosed prevalent population.
- In Japan, 128,408 diagnosed prevalent cases of AN were recorded in the year 2021, accounting for 16% of total cases in the 7MM.
Got queries? Click here to know more about the Anorexia Nervosa Market Landscape
Anorexia Nervosa Overview
Anorexia Nervosa (AN) is an eating disorder marked by weight loss (or a lack of proper weight gain in growing children), difficulty maintaining a healthy body weight for one’s height, age, and stature, and, in many cases, a distorted body image. Anorexics typically limit their calorie intake and the sorts of foods they consume. Anorexia falls into 2 general types: Restricting type: Anorexia nervosa patients with this kind of anorexia nervosa have extreme limits on the amount and type of food they eat. Excessive exercise may be associated with certain behaviors.Binge eating/purging type: People with this kind of anorexia restrict their food intake severely. However, this is often accompanied by binge eating followed by purging. The most evident evidence that someone has anorexia nervosa is that they are exceedingly underweight, have lost a lot of weight suddenly, or have a lot of weight fluctuations. Underweight is defined as a BMI of less than 18.5 kg/m2. However, being extremely thin is not the sole symptom of anorexia. There are various physical, psychological, and behavioral signs and symptoms shown by anorexics.
Anorexia Nervosa Epidemiology Insights
- As per the assessment of DelveInsight, in 2021, there were approximately 1,692,817 prevalent cases of AN in the 7MM. These cases are expected to increase during the forecast period.
- The total diagnosed prevalent cases of AN in the 7MM were observed to be 812,552 in 2021, these cases are expected to rise at a Compound Annual Growth Rate (CAGR) of 0.3% during the study period (2019–2032).
- In 2021, the total prevalent cases of AN in the US were observed to be approximately 703,497 cases, these cases are expected to rise at a decent CAGR during the study period.
- The highest diagnosed prevalent cases of AN were observed in the US as compared to EU-5 and Japan in the year 2021 and these cases are expected to increase in the forecast period.
Anorexia Nervosa Epidemiology Segmentation
- Total Anorexia Nervosa prevelant cases
- Total Anorexia Nervosa diagnosed prevelant cases
- Total Anorexia Nervosa Gender Specific diagnosed prevelant cases
Anorexia Nervosa Market Outlook
Anorexia Nervosa (AN) has a diverse genetic disposition as well as is determined by life phases such as puberty, problems in the family or with peers, trauma, and personality traits such as low self-esteem. It is characterized by extreme food restriction and an intense fear of gaining weight. Treatment usually involves several strategies, including psychological therapy, nutritional counseling, and/or hospitalization. Medications such as antidepressants, antipsychotics, or mood stabilizers may also be helpful for the treatment of eating disorders and other co-occurring illnesses such as anxiety or depression. Medications like olanzapine, aripiprazole, and dronabinol are generally used to manage patients, but there is no standard therapy available. Quetiapine is an atypical antipsychotic that, in low doses, can help with both psychological and physical improvements, with minimal associated side effects, and appears to be a promising candidate for the treatment of AN. Prozac can help with depressive symptoms and potentially with healthy weight maintenance once weight restoration is achieved. Prozac is part of the SSRI family or the selective serotonin uptake inhibitors that assist with increased serotonin levels connected to mood.
Learn more by requesting for sample @ Anorexia Nervosa Market Insight
Anorexia Nervosa Key Companies
- COMPASS Pathways
- Homeostasis Therapeutics
- And many more
Anorexia Nervosa Therapies
- Psilocybin
- Ketamine
- And many more
Market Drivers
- Growing worldwide prevalence.
- No approved drug.
- Collaboration between research institutes and pharmaceutical companies.
Market Barriers
- Lack of resources/funding.
- Guidelines and recommendations are focused on nonpharmacological therapies.
- Patients’ unacceptance of their medical condition.
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Anorexia Nervosa
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Anorexia Nervosa Emerging Therapies
- Anorexia Nervosa Market Outlook
- Market Access and Reimbursement of Therapies
- Market Drivers
- Market Barriers
- Appendix
- Anorexia Nervosa Report Methodology
- DelveInsight Capabilities
- Disclaimer
Click here to read more about Anorexia Nervosa Market Forecast
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/